Mentari adds $200M to migraine mission; Royalty’s latest ATTR-CM dealnews2026-07-22T14:17:01+00:00July 22nd, 2026|Endpoints News|
Q&A: Lilly returns to neuropsych and looks ahead to Alzheimer’s preventionnews2026-07-22T14:00:14+00:00July 22nd, 2026|Endpoints News|
Crystalys gets $130M to take Sobi-rivaling gout drug to marketnews2026-07-22T12:00:36+00:00July 22nd, 2026|Endpoints News|
Summit reports two-year survival data for Western patients, though context lackingnews2026-07-22T11:37:14+00:00July 22nd, 2026|Endpoints News|
Celldex scraps antibody in prurigo nodularis after Phase 2 flopnews2026-07-22T10:49:00+00:00July 22nd, 2026|Endpoints News|
Biopharma dealmaking in 2026: The recovery gathers speed in Q2news2026-07-22T10:45:36+00:00July 22nd, 2026|Endpoints News|
Vertex was only bidder for Crinetics in year’s second-highest M&A premiumnews2026-07-22T10:00:34+00:00July 22nd, 2026|Endpoints News|
Trump pledges new tariffs on generic drugs not made in the USnews2026-07-22T00:38:47+00:00July 22nd, 2026|Endpoints News|
Novo sues Lilly over ‘deceptive’ ads comparing GLP-1 drug dosesnews2026-07-21T18:57:43+00:00July 21st, 2026|Endpoints News|
Indian generic drugmaker gets FDA warning over clinical study consentnews2026-07-21T17:22:24+00:00July 21st, 2026|Endpoints News|
